Evelo Biosciences Inc Quick Ratio (EVLO) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Evelo Biosciences Inc   (NASDAQ: EVLO)

Evelo Biosciences Inc 's Quick Ratio

EVLO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Evelo Biosciences Inc 's Cash & cash equivalent grew by 126.48 % in the Q3 2023 sequentially, while Current Liabilities decreased, this led to improvement in Evelo Biosciences Inc 's Quick Ratio to 0.43, Quick Ratio remained below Evelo Biosciences Inc average.

Within Major Pharmaceutical Preparations industry 475 other companies have achieved higher Quick Ratio than Evelo Biosciences Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 2846, from total ranking in the second quarter 2023 at 3937.

Explain Quick Ratio?
How much Cash & cash equivalents EVLO´s has?
What are EVLO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EVLO Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change 60.72 % 173.33 % 288.15 % -34.23 % 31.25 %
Y / Y Cash & cash equivalent Change -75 % -91.72 % -30.68 % -29.95 % -28.02 %
Quick Ratio MRQ 0.43 0.14 0.5 4.73 2.79
EVLO's Total Ranking # 2846 # 3937 # 2182 # 736 # 1188
Seq. Current Liabilities Change -24.77 % -3.74 % 441.67 % -59.03 % 27.95 %
Seq. Cash & cash equivalent Change 126.48 % -72.26 % -42.7 % -30.58 % -24.95 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 476
Healthcare Sector # 905
Overall Market # 2846


Quick Ratio Statistics
High Average Low
24.76 8.12 0.14
(Mar 31 2018)   (Jun 30 2023)




Financial Statements
Evelo Biosciences Inc 's Current Liabilities $ 40 Millions Visit EVLO's Balance sheet
Evelo Biosciences Inc 's Cash & cash equivalent $ 17 Millions Visit EVLO's Balance sheet
Source of EVLO's Sales Visit EVLO's Sales by Geography


Cumulative Evelo Biosciences Inc 's Quick Ratio

EVLO's Quick Ratio for the trailling 12 Months

EVLO Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 114.11 % 110.55 % 69.31 % 4.92 % 8.45 %
Y / Y Cash & cash equivalent TTM Growth -62.73 % -48.62 % -27.76 % -39.7 % -34.79 %
Quick Ratio TTM 0.64 1.07 2.17 3.64 3.66
Total Ranking TTM # 3975 # 3293 # 3802 # 3559 # 3353
Seq. Current Liabilities TTM Growth 10.53 % 30.72 % 59.63 % -7.16 % 8.69 %
Seq. Cash & cash equivalent TTM Growth -34.05 % -35.68 % -4.89 % -7.62 % -9.08 %

Quick ratio ranking by company, industry and sector >> Back to EVLO Financial Strength Comparisons >> Go to Compare EVLO Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q3 2023 to $39.76 millions, cumulative Quick Ratio decreased to 0.64 below the Evelo Biosciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 533 other companies have achieved higher Quick Ratio than Evelo Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3293 to 3975.

Explain Quick Ratio?
How much Cash & cash equivalents EVLO´s has?
What are EVLO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 534
Healthcare Sector # 1075
Within the Market # 3975


trailing twelve months Quick Ratio Statistics
High Average Low
19.67 6.75 0.61
(Dec 31 2018)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Amphastar Pharmaceuticals Inc   1.17 $ 302.076  Millions$ 257.963  Millions
Longeveron Inc   1.16 $ 3.933  Millions$ 3.394  Millions
Biodexa Pharmaceuticals Plc  1.15 $ 8.147  Millions$ 7.097  Millions
Aeon Biopharma inc   1.14 $ 16.177  Millions$ 14.177  Millions
Intercept Pharmaceuticals inc   1.13 $ 102.736  Millions$ 90.845  Millions
Enveric Biosciences Inc   1.10 $ 4.267  Millions$ 3.883  Millions
Zoetis Inc   1.09 $ 1,754.000  Millions$ 1,608.000  Millions
Durect Corp  1.06 $ 38.985  Millions$ 36.752  Millions
Nature s Sunshine Products inc   1.04 $ 76.036  Millions$ 73.312  Millions
Calliditas Therapeutics Ab  1.04 $ 104.676  Millions$ 100.997  Millions
Skye Bioscience Inc   1.04 $ 14.211  Millions$ 13.719  Millions
Aquestive Therapeutics Inc   1.04 $ 24.917  Millions$ 24.057  Millions
Abbott Laboratories  1.03 $ 7,047.000  Millions$ 6,809.000  Millions
Xencor Inc  0.99 $ 52.733  Millions$ 53.041  Millions
Kineta Inc   0.99 $ 7.562  Millions$ 7.615  Millions
Avadel Pharmaceuticals Plc  0.99 $ 52.641  Millions$ 53.138  Millions
Protokinetix Incorporated  0.98 $ 0.012  Millions$ 0.013  Millions
Inflarx N V  0.98 $ 18.547  Millions$ 18.866  Millions
Heron Therapeutics Inc   0.97 $ 77.412  Millions$ 79.745  Millions
Biomarin Pharmaceutical Inc  0.97 $ 1,125.845  Millions$ 1,163.223  Millions
Clever Leaves Holdings Inc   0.95 $ 6.472  Millions$ 6.847  Millions
Unicycive Therapeutics Inc  0.93 $ 14.345  Millions$ 15.456  Millions
Corbus Pharmaceuticals Holdings Inc   0.91 $ 28.733  Millions$ 31.542  Millions
60 Degrees Pharmaceuticals Inc   0.91 $ 2.219  Millions$ 2.446  Millions
Reviva Pharmaceuticals Holdings Inc   0.90 $ 4.972  Millions$ 5.501  Millions
Phibro Animal Health Corporation  0.90 $ 91.153  Millions$ 101.366  Millions
Aravive Inc   0.87 $ 8.535  Millions$ 9.777  Millions
Aslan Pharmaceuticals Limited  0.86 $ 21.252  Millions$ 24.799  Millions
Jazz Pharmaceuticals Plc  0.85 $ 1,335.690  Millions$ 1,573.325  Millions
Esperion Therapeutics Inc   0.83 $ 114.833  Millions$ 137.708  Millions

Date modified: 2026-08-29T17:39:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.